03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc.’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research plan...
07:00 , May 22, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Berg's big data dive Berg Pharma LLC is seeking to validate its Interrogative Biology toolkit by striking academic partnerships with the University of Miami Miller School of Medicine and Medical University of South Carolina. Berg will...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Ferring, Merck, World Health Organization (WHO) deal

The partners entered a deal to advance a new formulation of Ferring's carbetocin to treat postpartum hemorrhage that is designed to be stable at room temperature, including in hot and tropical climates. The partners said...
02:02 , Dec 19, 2013 |  BC Extra  |  Financial News

Retrophin to raise $40 million, list on NASDAQ

Retrophin Inc. (OTCQB:RTRX) plans to raise up to $40 million in a follow-on and list its shares on NASDAQ. The move follows two deals the company announced earlier this month. Retrophin is acquiring Kyalin Biosciences...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Kyalin Biosciences, Retrophin, Novartis deal

Retrophin entered into two separate deals for oxytocin-based products to develop into treatments for autism and schizophrenia. Retrophin will acquire Kyalin for an undisclosed amount. Kyalin's most advanced product is an intranasal delivery form of...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

Carbetocin regulatory update

The European Commission granted Orphan Drug designation for Ferring's carbetocin to treat Prader-Willi syndrome. An IV and intramuscular formulation of carbetocin is marketed outside the U.S. as Duratocin, Lonactene and Pabal to treat postpartum hemorrhage....
07:00 , Aug 30, 2010 |  BC Week In Review  |  Company News

Cypress, Marina Biotech deal

Cypress acquired Marina's patent rights and technology related to an intranasal formulation of carbetocin. Cypress expects to start Phase II testing in 1Q11 for the long-acting analog of oxytocin to treat autism. Marina will receive...